Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Recent developments in the treatment of renal cell carcinoma.

Literature DB >> 24294292

Recent developments in the treatment of renal cell carcinoma.

Abstract

Renal cell carcinoma (RCC) management has been imbued with new interest, in large part due to the recent success of new treatment options for advanced and metastatic disease. This has also been accompanied by less generally well known advances in the understanding of the molecular characterizations of subtypes of RCC with potential to lead to new therapeutic options. Additionally, the urologic oncology community is focusing on nephron-sparing surgical approaches with limited surgery if possible, and in conjunction with interventional radiologists, on ablative procedures for incidentally determined small renal masses. This report reviews some of the new biologic findings of adenocarcinoma of the kidney, and reviews the new therapeutics which continue to change the landscape for treatment of RCC.

Entities: Disease

Keywords: Renal cell carcinoma; immunotherapy; molecular subtypes; targeted therapy

Year: 2013 PMID： 24294292 PMCID： PMC3825112 DOI： 10.1177/1756287213505672

Source DB: PubMed Journal: Ther Adv Urol ISSN： 1756-2872

95 in total

1. Commentary on: "Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial." Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer AG, Hariharan S, Escudier B. Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Joaquim Bellmunt, University Hospital del Mar-IMIM, Barcelona, Spain; Jill Clancy, Kongming Wang, Andreas G. Niethammer, Subramanian Hariharan, Pfizer, New York, NY; and Bernard Escudier, Institut Gustave Roussy, Villejuif, France.: J Clin Oncol. 2014 Mar 10;32(8):752-9; doi: 10.1200/JCO.2013.50.5305. [Epub 2013 Dec 2].

Authors: Donald Trump
Journal: Urol Oncol Date: 2015-04-30 Impact factor: 3.498

2. Clinical and genetic studies of Birt-Hogg-Dubé syndrome.

Authors: S K Khoo; S Giraud; K Kahnoski; J Chen; O Motorna; R Nickolov; O Binet; D Lambert; J Friedel; R Lévy; S Ferlicot; P Wolkenstein; P Hammel; U Bergerheim; M-A Hedblad; M Bradley; B T Teh; M Nordenskjöld; S Richard
Journal: J Med Genet Date: 2002-12 Impact factor: 6.318

3. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.

Authors: Andrew J Wagner; John M Goldberg; Steven G Dubois; Edwin Choy; Lee Rosen; Alberto Pappo; James Geller; Ian Judson; David Hogg; Neil Senzer; Ian J Davis; Feng Chai; Carol Waghorne; Brian Schwartz; George D Demetri
Journal: Cancer Date: 2012-05-17 Impact factor: 6.860

4. BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).

Authors: Keith T Flaherty; Judith B Manola; Michael Pins; David F McDermott; Michael B Atkins; Janice J Dutcher; Daniel J George; Kim A Margolin; Robert S DiPaola
Journal: J Clin Oncol Date: 2015-06-15 Impact factor: 44.544

5. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma.

Authors: Sakari Vanharanta; Mary Buchta; Sarah R McWhinney; Sanna K Virta; Mariola Peçzkowska; Carl D Morrison; Rainer Lehtonen; Andrzej Januszewicz; Heikki Järvinen; Matti Juhola; Jukka-Pekka Mecklin; Eero Pukkala; Riitta Herva; Maija Kiuru; Nina N Nupponen; Lauri A Aaltonen; Hartmut P H Neumann; Charis Eng
Journal: Am J Hum Genet Date: 2003-12-18 Impact factor: 11.025

6. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.

Authors: Michael S Gordon; Michael Hussey; Raymond B Nagle; Primo N Lara; Philip C Mack; Janice Dutcher; Wolfram Samlowski; Joseph I Clark; David I Quinn; Chong-Xian Pan; David Crawford
Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544

7. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.

Authors: Joseph I Clark; Michael B Atkins; Walter J Urba; Steven Creech; Robert A Figlin; Janice P Dutcher; Larry Flaherty; Jeffrey A Sosman; Theodore F Logan; Richard White; Geoffrey R Weiss; Bruce G Redman; Christopher P G Tretter; David McDermott; John W Smith; Michael S Gordon; Kim A Margolin
Journal: J Clin Oncol Date: 2003-06-16 Impact factor: 44.544

8. Nivolumab plus ipilimumab in advanced melanoma.

Authors: Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal: N Engl J Med Date: 2013-06-02 Impact factor: 91.245

9. Renal medullary carcinoma. The seventh sickle cell nephropathy.

Authors: C J Davis; F K Mostofi; I A Sesterhenn
Journal: Am J Surg Pathol Date: 1995-01 Impact factor: 6.394

10. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors: Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal: Cancer Res Date: 2004-10-01 Impact factor: 13.312

32 in total

Review 1. The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.

Authors: Tamina Seeger-Nukpezah; Daniel M Geynisman; Anna S Nikonova; Thomas Benzing; Erica A Golemis
Journal: Nat Rev Nephrol Date: 2015-04-14 Impact factor: 28.314

2. Antitumour and antiangiogenic activities of [Pt(O,O'-acac)(γ-acac)(DMS)] in a xenograft model of human renal cell carcinoma.

Authors: A Muscella; C Vetrugno; F Biagioni; N Calabriso; M T Calierno; F Fornai; S A De Pascali; S Marsigliante; F P Fanizzi
Journal: Br J Pharmacol Date: 2016-07-22 Impact factor: 8.739

3. Prognostic investigations of B7-H1 and B7-H4 expression levels as independent predictor markers of renal cell carcinoma.

Authors: Hamid Reza Safaei; Ayoob Rostamzadeh; Omid Rahmani; Mohsen Mohammadi; Omar Ghaderi; Hamid Yahaghi; Koroosh Ahmadi
Journal: Tumour Biol Date: 2015-12-18

4. Increased expression of metastasis-associated in colon cancer-1 in renal cell carcinoma is associated with poor prognosis.

Authors: Zhong Jin; Naijin Xu; Kai Guo; Peng Xu; Pengju Li; Yiming Zhang; Xiezhao Li; Shaobo Zheng; Chunxiao Liu; Abai Xu; Peng Huang
Journal: Int J Clin Exp Pathol Date: 2015-04-01